KBC Group
ELVN icon

KBC Group’s Enliven Therapeutics ELVN Stock Holding History

KBC Group’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$83K Hold
1,805
– – ﹤0.01% 1498
2026
Q2 		$92K Buy
1,805
+847
+88% +$36K ﹤0.01% 1468
2026
Q1 		$38K Buy
+958
New +$26.5K ﹤0.01% 1738

Other funds holding ELVN

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
TimesSquare Capital Management
TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Tema ETFs
Tema ETFs New York $2.69B AUM 42.96% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

KBC Group's ELVN Position: Q3 2026 in Review

KBC Group held its Enliven Therapeutics (ELVN) position steady in Q3 2026 at 1,805 shares worth $83K. The position accounts for ﹤0.01% of the portfolio, ranked #1498.

KBC Group first reported a position in ELVN in Q1 2026 and has held it in 3 quarters since. The position peaked at $92K in Q2 2026. 54 funds tracked by Wall St. Rank hold ELVN as of Q3 2026.

  • KBC Group held 1,805 shares of Enliven Therapeutics worth $83K as of Q3 2026.
  • KBC Group left its Enliven Therapeutics share count unchanged in Q3 2026.
  • Enliven Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q3 2026, its #1498 holding.
  • KBC Group first reported a position in Enliven Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • KBC Group's Enliven Therapeutics position peaked at $92K in Q2 2026.
  • 54 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q3 2026.

Based on KBC Group's 13F filing for Q3 2026, filed 22 Oct 2026.